Research Article

Angiotensin II Mediates Cardiomyocyte Hypertrophy in Atrial Cardiomyopathy via Epigenetic Transcriptional Regulation

Liuying Zheng,1,2 Jin Wang,3 Rui Zhang,2 Yingyi Zhang,2 Jie Geng,2 Lu Cao,2 Xiaoyun Zhao,1,4,5,6 Jianhui Geng,7 Xinpeng Du,8 Yuecheng Hu,2 and Hongliang Cong1,2

1Tianjin Medical University, Heping District, Tianjin 300070, China
2Department of Cardiology, Tianjin Chest Hospital, Jinnan District, Tianjin 300222, China
3Cardiac Surgery, Peking University First Hospital, Xicheng District, Beijing 100034, China
4Department of Respiratory Critical Care Medicine and Sleep Center, Tianjin Chest Hospital, Tianjin 300222, China
5Tianjin University, Tianjin 300072, China
6Tianjin Tiangong University, Life Science School, Tianjin 30387, China
7Shanxi Cardiovascular Hospital, 18 Yifen Street, Taiyuan, 030024 Shanxi, China
8Department of Cardiology, The Fifth Central Hospital of Tianjin, Binhai Hospital of Peking University, Binhai New Area, Tianjin 300450, China

Correspondence should be addressed to Yuecheng Hu; hwhitecrane@163.com and Hongliang Cong; hongliangcong@163.com

Received 4 April 2022; Revised 11 May 2022; Accepted 16 May 2022; Published 17 June 2022

Academic Editor: Xiucai Ye

Copyright © 2022 Liuying Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims. European Heart Rhythm Association established an expert consensus to define, characterize, and classify atrial cardiomyopathy into four subgroups based on their histopathological features. The predominant pathological feature of classes I and III is the hypertrophy of atrial cardiomyocytes. Here, we aim to investigate the mechanism of epigenetic transcriptional regulation of cardiomyocyte hypertrophy in atrial cardiomyopathy. Methods and Results. Compared with that of sinus rhythm control individuals, the myocardium of patients with atrial fibrillation exhibited increased levels of angiotensin II (AngII), chromatin-bound myocyte enhancer factor 2 (MEF2), acetylated histone H4 (H4ac), and H3K27ac; upregulation of hypertrophy-related genes; and decreased levels of histone deacetylase (HDAC) 4 and HDAC5 bound to the promoters of hypertrophy-related genes. Furthermore, incubation of atrial cardiomyocytes with AngII increased their cross-sectional area and improved the expression of hypertrophy-related genes. AngII also promoted the phosphorylation of HDAC4 and HDAC5 and induced their nuclear export. RNA sequencing analyses revealed that AngII significantly upregulated genes associated with cardiac hypertrophy. Chromatin immunoprecipitation showed that this correlated with increased levels of chromatin-bound MEF2, H4ac, and H3K27ac and decreased HDAC4 and HDAC5 enrichment in the promoters of hypertrophy-related genes. Moreover, these AngII-induced prohypertrophic effects could be partially reverted by treatment with the AngII receptor blocker losartan. Conclusions. AngII had a prohypertrophic effect on atrial cardiomyopathy which was epigenetic-dependent. Patients with atrial fibrillation manifest an increased susceptibility to hypertrophy and exhibit epigenetic characteristics that are permissive for the transcription of hypertrophy-related genes. AngII induces histone acetylation via the cytoplasmic-nuclear shuttling of HDACs, which constitutes a novel mechanism of atrial hypertrophy regulation and might provide a promising therapeutic strategy for atrial cardiomyopathy.
1. Introduction

From the first observation as “auricle” by Harvey [1] in 1628 to the latest definition as “atrial failure” by Bisbal et al. [2] in 2020, we went through a nearly 400-year journey of atrial study. The evolution of the atrial pathophysiological terms has experienced “atrial remodelling” [3], “atrial fibrillation (AF)” [4], “atrial cardiomyopathy” [5], “atrial dysfunction” [2], etc. AF constitutes the most commonly encountered arrhythmia in clinical practice and a major cause of mortality [4]. Structural remodelling is the main contributing mechanism and hallmark of AF [2, 3], and we have shown that stress-induced atrial structural remodelling in particular plays an important role in AF progression [6, 7]. In 2016, the European Heart Rhythm Association and four other associations define, characterize, and classify atrial cardiomyopathy into four subgroups based on their histopathological features [5]. The working group proposed the following working definition of atrial cardiomyopathy: "Any complex of structural, architectural, contractile, or electrophysiological changes affecting the atria with the potential to produce clinically relevant manifestations" [5], emphasizing the close correlation among structural, electrophysiological, and functional remodelling in atrial pathogenic substrates. However, the mechanisms underlying atrial cardiomyopathy initiation and progression have not been systematically delineated. Better understanding of atrial cardiomyopathy pathogenesis may foster breakthroughs in the therapeutic treatment of atrial dysfunction, AF, and cardiogenic stroke.

The predominant pathological feature of class I and III atrial cardiomyopathy is atrial cardiomyocyte hypertrophy [5]. Cardiomyocytes are terminally differentiated and lose their capacity to proliferate soon after birth. Thereafter, cardiomyocytes grow in size without cell proliferation to adapt to the demand for overload. In several pathological conditions (e.g., hypertension, valvular disease, and myocardial infarction) that impose overwork on the heart, postnatal cardiomyocytes undergo cardiac hypertrophy. Although initially compensatory for overload, prolongation of this stressed process leads to congestive heart failure, arrhythmia, and sudden death [8]. At the cellular level, cardiac hypertrophy is characterized by an increase in cell size and reactivation of the foetal gene program [9].

Angiotensin II (AngII) is a major effector peptide in angiotensin system (RAS), which usually stimulates hypertrophy [10]. Hypertrophic stimuli initiate a number of subcellular signalling pathways that eventually lead to altered cardiac myocyte gene expression via transcription factors including myocyte enhancing factor-2 (MEF2) [11] and a zinc finger protein, GATA-4 [12]. Increasing evidence also suggests that epigenetic mechanisms are involved in RAS-induced cardiac remodelling [13]. Epigenetic regulation such as histone (H3 and H4) lysine acetylation (H3Kac and H4Kac) plays an important role in gene transcription regulation, while histone deacetylase (HDAC) promotes chromatin structural condensation, leading to transcriptional suppression [14, 15].

Transcription factor MEF2 associates with class II HDACs via an 18-amino-acid motif [16, 17]. Class II HDACs form a complex with MEF2 via gene regulatory elements, resulting in repression of genes transcription by harbouring MEF2-binding sites [18]. HDACs shuttled from the nucleus to the cytoplasm in response to stress, providing an epigenetic mechanism to override HDAC-mediated repression of cardiac growth [19]. This redistribution of HDACs enables MEF2 and other transcriptional activators to associate with histone acetyltransferase (HAT) [20] resulting in increased local histone acetylation and activation of downstream genes that facilitate cellular growth.

However, the nuclear transcriptional mechanism of AngII signalling as well as the potential involvement of epigenetic chromatin remodelling in cardiac hypertrophy remain unexplored. In the present study, we showed that atrial samples from patients with AF displayed increased susceptibility to hypertrophy and epigenetic characteristics that are permissive for hypertrophy-related gene transcription. In primary neonatal cardiomyocytes, we showed that by inducing cytoplasm nuclear shuttling of HDACs, AngII regulates histone acetylation, promoting MEF2 binding to the promoter of hypertrophy-related genes and representing a novel mechanism for atrial hypertrophy.

2. Methods

2.1. Experimental design. Animal care and isolation procedures were approved by the Animal Ethics Committee of the 5th Central Hospital of Tianjin, China, and were performed according to the European Directive on Laboratory Animals (86/609/EEC). All experimental procedures were performed according to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996) and were in compliance with the guidelines specified by the Chinese Heart Association policy on the use of research animals and the Public Health Service policy on the use of laboratory animals.

2.2. Human Atrial Samples. Consecutive patients with valvular heart disease who underwent mitral or aortic valve replacement or coronary artery bypass grafting were recruited. Patients taking angiotensin converting enzyme inhibitors and/or angiotensin II-receptor blockers (ARBs) were excluded from the study. Overall, a total of eight patients with chronic persistent atrial fibrillation (AF group) and seven patients without a history of AF (sinus rhythm, SR group) were recruited. All patients underwent echocardiography before the surgery. Samples of right atrial appendages were obtained during open-heart surgery, quickly frozen in liquid nitrogen, and maintained at −80°C until used for mRNA and protein analysis. The study protocol was approved by the Ethics Committee of 5th Central Hospital of Tianjin, China. The research protocol was registered through the audit of Chinese Clinical Trial Registry (registration number: ChiCTR-COC-17013241). All study subjects provided informed consent prior to the inclusion of people in the study. The investigation conformed to the principles outlined in the Declaration of Helsinki.

2.3. Atrial Cardiomyocyte Culture. Primary neonatal atrial rat cardiomyocytes were isolated from 1–3-day-old
Sprague-Dawley rats as described [21]. Briefly, neonatal rats were euthanized by decapitation, the atrium was dissected, minced, and digested with trypsin and collagenase, and the isolated cells were preplated twice for 60 min to eliminate fibroblasts. The nonadherent myocytes were then plated in plating medium containing 199 media supplemented with HEPE, MEM nonessential amino acids, glucose, glutamine, 10% foetal bovine serum, vitamin B12, penicillin, and streptomycin on fibronectin-coated plates. Following overnight culture, cells were washed, and fresh medium with 2% foetal calf serum was added.

2.4. Western Blotting. Proteins were size-fractionated on 8–12% sodium dodecyl sulphate-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked by 5% nonfat dry milk (NFDM) in phosphate-buffered saline (PBS) and incubated for 1 h at room temperature (RT). Membranes were washed with PBS containing 0.5% Tween-20, incubated with primary antibodies overnight, and then incubated with horseradish peroxidase- (HRP-) conjugated secondary antibody for 1 h. Antibodies against atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), beta-myosin heavy chain (β-MHC), skeletal alpha-actin (SKA), MEF2, P-HDAC4 (S632), P-HDAC5 (S548), HDAC4, HDAC5, H3K27ac (anti-Histone H3K27), and H4ac (acetyl-Histone H4K5, 8, 12, 16) were purchased from Abcam (Cambridge, UK). Antibodies against P-HDAC5 (S498), HDAC4, HDAC5, H3K27ac (anti-Histone H3K27), and H4ac (acetyl-Histone H4K5, 8, 12, 16) were purchased from Cell Signaling Technology (Mountain View, CA, USA). HRP-goat anti-rabbit IgG secondary antibodies were obtained from SaierBio Technology Inc. (Tianjin, China). The images were captured on a UVP Biolimaging System, and GAPDH was used as an internal control.

2.5. Immunofluorescence. Cultured atrial cardiomyocytes were washed with PBS and fixed with 4% paraformaldehyde for 30 min. After 3 washes with PBS for 5 min each, permeabilization of cell membranes was accomplished by applying 0.1% triton X in 0.5% NFDM supplemented with 1% foetal calf serum in PBS for 30 min at RT. Permeabilized cells were incubated with rabbit anti-α-actin, HDAC4, or HDAC5 antibody (1:800) diluted in 0.1% triton X, 1% NFDM, and 1.4% normal calf serum in PBS overnight at 4°C. Primary antibodies were withdrawn the next day, and cells were washed twice with 1X PBS for 5 min at RT. Secondary antibody FITC- or TRITC-labelled goat anti-rabbit was diluted (1:1,000) in the same primary antibody solution and applied to the cells for 1 h at RT. Cells were washed twice (1X PBS) and visualized and imaged using the ECLIPSE Ts2-FL fluorescence microscopy (Nikon, Tokyo, Japan).

2.6. Chromatin Immunoprecipitation (ChIP). ChIP was performed according to the manufacturer’s instructions. Briefly, atrial cardiomyocytes were fixed with 1% formaldehyde for 10 min at 37°C. Chromatin was sonicated, yielding DNA fragments of 200–800 bp. After preclearing with protein A/G agarose at 4°C for 1 h, samples were incubated with 10 μg HDAC4, HDAC5, MEF2, H3K27ac, or H4ac antibody or IgG (as a control) with rotation at 4°C overnight. The cross-linking was reversed by incubation in 5 M NaCl/protease K solution at 65°C for 2 h. Precipitated DNA was purified using spin columns and subjected to polymerase chain reaction (PCR) analysis. Real-time PCR was performed using iQ SYBR Green Supermix and the iCycler real-time PCR detection system (Bio-Rad). The reaction conditions were as follows: denaturation at 95°C for 10 min, followed by 40 cycles of amplification and quantification at 95°C for 30 s, 60°C for 30 s, and 72°C for 1 min. The conditions of the melting curve analysis were as follows: 95°C for 15 s, 60°C for 15 s, and 95°C for 15 s. The primers used for PCR to identify the ANP and BNP promoter-binding sequence were as follows: ANP forward-5′-CGT TGC CAG GGA GAA GGA3′, reverse-5′-CAT TCT GTC ACT TGC GGC G3′; BNP forward-5′-GCT CAG CAG GCA GGA ATG3′, reverse-5′-TAG CCT CTC AGC AAC GGT G3′.

2.7. ELISA Assay. Frozen heart tissue samples were weighed, homogenized using an electric homogenizer on ice in PBS, and centrifuged at 10,000 g for 20 min at 4°C. The supernatant was used for subsequent ELISA analyses. AngII levels were measured in a 96-well plate by a sandwich ELISA method using a kit from Elabscience (Houston, TX, USA). For the assay, 100 μL of standard and sample was added to wells that were coated with antibodies before incubation. The final concentrations were calculated by interpolation from standard curves according to the manufacturer’s instructions.

2.8. Construction of Recombinant Adenovirus. The full-length DNAs of the HDAC4 and HDAC4-mut (S246A, S632A) genes with BglII and XbaI cleavage sites and HDAC5 and HDAC5-mut (S259A, S498A) genes with added KpnI and HindIII sites were synthesized by Genewiz (South Plainfield, NJ, USA) and ligated with the adenovirus shuttle plasmid pAdTrack-CMV (Stratagene, La Jolla, CA). These constructs were then linearized with Pmel and homology-recombined in AdEasier-1 cells, a derivative of BJ5183 bacteria already containing the adenovirus backbone plasmid pAdEasy-1 (Stratagene/Agilent Technologies, Santa Clara, CA, USA). Positive clones were selected for culture, plasmid extraction, and PacI digestion. The larger fragment was recovered using a gel extraction kit and transfected into HEK293 cells via liposomes (Lipofectamine™ 2000; Invitrogen, Carlsbad, CA). After 8 or 10 days, the recombinant adenovirus was collected. The TCID50 method was used to calculate the adenovirus titre. Subsequently, cardiomyocytes were infected using a multiplicity of infection of 50.

2.9. RNA-Seq. Total RNA from cell and heart tissue samples was extracted using a TRizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. Genome-wide rat gene expression profiling was performed using RNA deep sequencing by Annoroad Gene Technology Co., Ltd. (Beijing, China). Library construction was...
Table 1: Patient characteristics.

|                  | Sex | Age (year) | Protopathy              | LVEF (%) | LA (mm) | RA (mm) | LV (mm) | Hypertension | Diabetes mellitus | Drugs                                      |
|------------------|-----|------------|-------------------------|----------|---------|---------|---------|--------------|------------------|--------------------------------------------|
| Sinus rhythm (n = 7) | M   | 29         | Bicuspid aortic valves  | 73.0     | 3.4     | 3.3     | 7.2     | No           | No               | Diuretics                                  |
|                  | F   | 62         | Coronary heart disease  | 37.2     | 3.7     | 3.9     | 3.9     | Yes          | Yes              | Diuretics, calcium-channel blockers; nitrates |
|                  | M   | 80         | Coronary heart disease  | 44.6     | 3.9     | 4.3     | 5.0     | Yes          | No               | Diuretics, nitrates                          |
|                  | M   | 70         | Coronary heart disease  | 61.5     | 5.0     | 4.6     | Yes     | Yes          | No               | Calcium-channel blockers; nitrates           |
|                  | F   | 76         | Coronary heart disease  | 45.1     | 3.2     | 4.2     | Yes     | Yes          | No               | Nitrates                                    |
|                  | F   | 57         | Coronary heart disease  | 76.1     | 3.7     | 4.4     | Yes     | No           | No               | Calcium-channel blockers; nitrates           |
|                  | M   | 52         | Coronary heart disease  | 48.7     | 4.0     | 4.0     | 5.3     | Yes          | No               | Nitrates                                    |
|                  |     |            |                         | 44.8 ± 23.4 | 3.8 ± 0.6 | 3.9 ± 0.4 | 4.9 ± 1.1 |            |                  |                                             |
| Mean ± SD        |     | 60.9 ± 17.3 |                         | ...      | ...     | ...     | ...     | ...          | ...              | ...                                        |
| AF (n = 8)       | F   | 66         | Mitral valve prolapse   | 79.4     | 6.4     | 5.3     | 6.2     | Yes          | No               | Diuretics                                  |
|                  | M   | 71         | Mitral valve prolapse   | 61.2     | 5.8     | 6.5     | 5.7     | Yes          | No               | Diuretics, nitrates                          |
|                  | M   | 56         | Coronary heart disease  | 47.4     | 4.0     | 5.0     | 5.7     | No           | No               | No                                         |
|                  | M   | 51         | Atrial septal defect    | 59       | 5.5     | 6.5     | 4.6     | No           | No               | Diuretics                                  |
|                  | F   | 64         | Mitral stenosis         | 48.6     | 4.6     | 5.8     | 4.0     | No           | No               | Diuretics                                  |
|                  | M   | 77         | Atrial fibrillation     | 51.8     | 5.1     | 5.7     | 6.1     | Yes          | Yes              | Calcium-channel blockers; nitrates           |
|                  | F   | 79         | Coronary heart disease  | 68.3     | 4.0     | 5.4     | 4.8     | No           | Yes              | Nitrates, diuretics                          |
|                  | F   | 54         | Mitral regurgitation    | 50.7     | 5.1     | 5.0     | 5.7     | No           | Yes              | Calcium-channel blockers; nitrates           |
| Mean ± SD        |     | 64.8 ± 10.5 |                         | ...      | 58.3 ± 11.1 | 5.1 ± 0.8* | 5.7 ± 0.6* | 5.4 ± 0.8 | ...          | ...                                         |

M: male; F: female; LVEF: left ventricular ejection fraction; LA: left atrium; RA: right atrium; LV: left ventricle; *P < 0.05 vs. the sinus rhythm.
performed following the manufacturer’s instructions provided by Illumina (San Diego, CA, USA). Samples were sequenced on an Illumina HiSeq 4000 instrument. Clean data were used in further analyses. Tophat2 [22] was used to map clean reads to the genome of rn5. Differentially expressed genes (DEGs) were identified using HTSeq [23] and edgeR package [24]. A fold change > 1.5 and false discovery rate (FDR) < 0.05 were considered significant. Finally, a heatmap was generated in the R language.

2.10. Statistical Analysis. Data are expressed as means ± SD. An unpaired Student’s t test was used for statistical comparison between two groups after the demonstration of homogeneity of variance with an F test, and one-way ANOVA was used for comparison of more than two groups. A value of $P < 0.05$ was considered statistically significant.

3. Results

3.1. Patients with AF Manifest Increased Susceptibility to Hypertrophy and Display Atrial Hypertrophy. The clinical characters of the study subjects are shown in Table 1. The AF group exhibited greater mean atrial dimensions than the SR group, suggesting atrial hypertrophy in patients with AF. As AngII constitutes a major effector peptide of RAS, which contributes to cardiac hypertrophy pathogenesis [25], we measured the atrial tissue AngII concentration to investigate the status of RAS. Atrial tissue AngII concentration was significantly elevated (Figure 1(a)), which indicated the activation of RAS in patients with AF and suggested that the environment of atrial tissue itself in these patients may stimulate cardiomyocyte hypertrophy. To determine the presence of the foetal gene expression program associated with cardiac hypertrophy [8, 9], we quantified the products of hypertrophy-related genes ANP and BNP in the atrial tissue of AF and SR groups. An increase in ANP and BNP protein expression was detected in the AF compared to SR atrial samples (Figure 1(b)).

3.2. Atrial Tissue in Patients with AF Exhibits Epigenetic Characteristics Permissive for Hypertrophy-Related Gene Transcription. Among the intracellular pathways that integrate mechanical and hormonal signals, MEF2 plays prominent regulatory roles in cardiac hypertrophy and remodelling [26, 27]. Atrial samples from patients with AF showed greater enrichment of MEF2 bound to the promoters of hypertrophy-related genes ANP and BNP than that in SR samples (Figure 2). Class II HDAC isoforms, such as HDAC4

Figure 1: Tissue levels of AngII and levels of proteins encoded by hypertrophy-related genes ANP and BNP from right atrial appendages are higher in patients with atrial fibrillation (AF) than those with sinus rhythm (SR). (a) Tissue levels of AngII were measured by ELISA. (b) Tissue levels of ANP and BNP were measured by western blotting. $N = 5$ per group. Data are shown as the means ± SD. Statistical significance was determined by one-way ANOVA followed by the Bonferroni posttest. *$P < 0.05$ vs. the N group.
ANP/INPUT (Relative abundance)

2.5
2.0
1.5
1.0
0.5
0.0

SR AF SR AF SR AF SR AF SR AF

Anti-H4Ac Anti-H3K27Ac Anti-HDAC5 Anti-HDAC4 Anti-MEF2

⁎ ⁎ ⁎ ⁎⁎

SR AF SR AF

Anti-H4 ac

Anti-H3K27 ac

Anti-HDAC5

Anti-HDAC4

Anti-MEF2

Input

(a)

Figure 2: Continued.
and HDAC5, act as signal-responsive repressors of nuclear MEF2 activity in cardiac myocytes, with their spatial regulation providing a key mechanism for the neurohormonal control of such activity [28, 29]. We observed decreased chromatin-bound HDAC4 and HDAC5 on both ANP and BNP promoters (Figures 2(a) and 2(b)), indicating a permissive state for histone acetylation in atrial tissue from patients with AF compared to SR.

To further explore tissue-specific histone modification patterns in AF and SR, we analyzed the H3K27ac and H4ac enrichment at the promoter of ANP (a) and BNP (b) from chromatin isolated from AF or N atrial tissue. Histone modifications H3K27ac and H4ac, which have been associated with activation of gene expression, were measured at ANF (a) and BNP (b) gene promoters by ChIP. N = 3 per group. Data are shown as the means ± SD, statistical significance was determined by one-way ANOVA followed by the Bonferroni posttest. *P < 0.05 vs. N group. All ChIP data are plotted as fold enrichment over equivalent amounts of input DNA, H3K27ac:H3 Lys27 acetylation, and H4ac:H4 Lys acetylation.

3.3. AngII Induces Hypertrophy of Atrial Cardiomyocytes. At the cellular level, hypertrophy is accompanied by an increase in cardiomyocyte size and reinduction of a foetal cardiac gene program that ultimately weakens cardiac performance [30, 31]. Thus, the reinduction of foetal genes (encoding ANP, BNP, β-MHC, and SKA) is employed as a marker of hypertrophy [32]. Incubation with AngII resulted in an
Figure 3: Continued.
Figure 3: AngII-induced atrial cardiomyocyte hypertrophy. Atrial cardiomyocytes were stimulated with saline, AngII, AngII + losartan, AngII + the PKD inhibitor CID755673, or AngII + the CaMKII inhibitor KN93 for 48 h and subjected to immunofluorescence staining with antibody against α-actin. (a) Cell surface area of atrial cardiomyocytes treated with different stimuli was examined. The mean surface area of atrial cardiomyocytes after treatment was obtained from 200 atrial cardiomyocytes per sample. (b) Atrial cardiomyocyte extracts from different groups were subjected to western blotting using anti-ANP, BNP, SKA, and β-MHC antibodies. Data are plotted as fold enrichment over equivalent amounts of GAPDH. Data are shown as the means ± SD. *P < 0.05. N = 3 per group. Statistical significance was determined by one-way ANOVA followed by the Bonferroni posttest. Mock: saline, Ang + PKD: AngII + PKD inhibitor CID755673, and Ang + CaMKII: AngII + CaMKII inhibitor KN93.
Figure 4: Continued.
Figure 4: Continued.
increase in the cell cross-sectional area of atrial cardiomyocytes (Figure 3(a)). AngII-treated cardiomyocytes also showed significantly increased level of proteins encoded by hypertrophy-related genes compared with the control (Figure 3(b)). Conversely, the AngII-induced atrial cardiomyocyte hypertrophy and hypertrophy-related gene reaction could be alleviated by ARB losartan (100 μmol/L; Merck Sharp & Dohme Corp., Cramlington, UK).

3.4. AngII Induces HDAC4 and HDAC5 Phosphorylation and Nuclear Export. Numerous extracellular agonists and, in particular, those that act through G-protein-coupled receptors, such as adrenergic agonists, endothelin, and angiotensin, promote cardiomyocyte hypertrophy by modulating the activities of chromatin remodelling enzymes, which act as global regulators of the cardiac genome during pathological remodelling of the heart [33–35]. However, class II HDAC levels do not change in stressed myocardium [36]. Instead, these HDACs are shuttled from the nucleus to the cytoplasm in response to stress signals, suggesting a posttranslational mechanism to cardiac growth repression [19]. We found that HDAC4 and HDAC5 were located in the nucleus in approximately 90% of atrial cardiomyocytes under basal conditions. In contrast, AngII incubation caused HDAC4 and HDAC5 to translocalize and accumulate in the cytosol (Figures 4(a) and 4(b)), although total protein levels did not appear to change.

Class II HDACs share high structural homology in the region surrounding the phosphorylation sites in their N-terminal domains which contain docking sites for 14-3-3 proteins. Phosphorylation of their signal-responsive serine results in their nuclear exclusion in a 14-3-3 protein-dependent manner [37–39]. AngII incubation increased HDAC4 and HDAC5 phosphorylation on their signal-responsive serine sites (Figure 4(c)), suggesting that AngII may phosphorylate HDAC4 and HDAC5 to induce their nuclear exportation and cytoplasmic accumulation.

3.5. AngII Increases Chromatin Acetylation and MEF2 Enrichment on Hypertrophy-Related Gene Promoters by Excluding HDAC4 and HDAC5. We next tested whether AngII-induced nuclear export of class II HDACs would inhibit the binding of class II HDACs to the promoter region of hypertrophy-related genes. The ChIP assay showed that AngII decreased HDAC4 and HDAC5 binding to the hypertrophy-related gene promoters (Figure 5). The functional bridge connection between chromatin modifiers and signalling mediators is established through transcription factors [40] such as MEF2, which is found in many protein complexes that are involved in gene activation under...
followed by the Bonferroni posttest.

means ± SD

ANP

H3K27ac and H4ac enrichment at promoters of ANP hypertrophy-related genes

The kinase(s) that

3.6. AngII-Induced CaMKII/PKD Pathway Activation Results in promoters and activation of downstream hypertrophy-related

ingenomes that promote hypertrophy of atrial cardiomyocytes.

increased histone acetylation of chromatin on local pro-

empowers MEF2 and other transcriptional activators to

mutually exclusive [45]. We further found that AngII

evolving HDACs and subsequent release of MEF2-

pathological conditions by modifying histones [41, 42]. As
class II HDACs form a complex with MEF2 resulting in
repression of genes harboring MEF2-promoter-binding

sites [18, 43, 44], we tested the enrichment of MEF2 binding
to the promoter region of hypertrophy-related genes. ChiP

assay demonstrated that AngII treatment promoted MEF2

binding to the promoter region of hypertrophy-related
genases, perhaps owing to AngII-induced nuclear export of
class II HDACs and subsequent release of MEF2-

promoter-binding sites.

HAT has also been shown to associate with the same
domain of MEF2 that is also dominated by class II HDACs,
although the interaction of MEF2 with HATs and HDACs is
mutually exclusive [45]. We further found that AngII
enhanced chromatin H4ac and H3K27ac modification levels
on the MEF2-promoter-binding sites of hypertrophy-related
genomes, suggesting that AngII may facilitate MEF2 binding
and acetylation of chromatin histones on the promoter of
hypertrophy-related genes by excluding HDAC4 and
HDAC5. This AngII-induced redistribution of HDACs
empowers MEF2 and other transcriptional activators to
approach and associate with HATs [20], resulting in
increased histone acetylation of chromatin on local pro-
moters and activation of downstream hypertrophy-related
genomes that promote hypertrophy of atrial cardiomyocytes.

3.6. AngII-Induced CaMKII/PKD Pathway Activation Results in HDAC4 and HDAC5 Nuclear Export. The kinase(s) that

phosphorylate class II HDACs has become the focus of cardiac hypertrophy study because they coupled extracellular stimuli to the intracellular genome by governing class II HDAC nuclear localization and function. CaM kinases and protein kinase D (PKD) have been implicated in hypertrophy and heart failure in rodents and humans [46]. We hypothesized that CaMKII and PKD may deliver hypertrophic signals from the G-protein-coupled receptors of AngII to class II HDAC phosphorylation sites. Inhibition of CaM-KII and PKD kinase function using the respective inhibitors KN93 (5 μmol/L) and CID755673 (20 μmol/L) partially prevented AngII-induced atrial cardiomyocyte hypertrophy and alleviated AngII-induced reexpression of hypertrophy-related genes (Figures 3(a) and 3(b)). CaMKII and PKD inhibitors could also decrease HDAC4 and HDAC5 phosphorylation and nuclear export (Figures 4(a) and 4(b)). These results suggested that AngII selectively targeted specific class II HDACs partially in a CaMKII- and PKD-dependent manner with consequent induction of atrial hypertrophy.

3.7. Class II HDAC Dephosphorylation Retards Their Nuclear Export and Antagonizes AngII-CaMKII/PKD-HDAC Signalling. Dephosphorylation of these sites antagonizes AngII-CaMKII/PKD-HDAC signalling, promoting class II HDAC nuclear retention. We mutated the serine phosphorylation sites of HDAC4 and HDAC5 and infected atrial cardiomyocytes with adenovirus harbouring mutated
Figure 6: Continued.
(lacking the three CaMKII/PKD phosphorylation sites) or wild-type (wt) versions of these proteins (Ad-mut-HDAC4, Ad-mut-DHAC5, Ad-HDAC4, or Ad-HDAC5) (Figure 6(a)). As expected, overexpression of Ad-HDAC4 and Ad-HDAC5 strongly repressed AngII-induced hypertrophy-related gene expression (Figures 6(b) and 6(c)), whereas HDAC4-mut and HDAC5-mut further strengthened the repression of AngII-induced hypertrophy-related gene expression (Figures 6(b) and 6(c)).

3.8. Atrial Energy Remodelling May Constitute an Upstream Influencer of Structural Remodelling. Mitochondrial energy dysfunction is also suggested as an atrial arrhythmogenic substrate [47, 48]. To assess the status of cardiac mitochondrial metabolism-related genes in AF, atrial cardiomyocytes were incubated with AngII for 48 h and subjected to RNA-Seq. Cardiac mitochondrial metabolism-related genes changed more extensively than cardiac structural genes under pathological hypertrophic conditions (Figure 7). Notably, these AngII-induced atrial energy remodelling changes could be reversed by the ARB losartan.

4. Discussion

4.1. Patients with Atrial Cardiomyopathy Display Atrial Hypertrophy. We have demonstrated that AngII-induced atrial structural remodelling plays an important role in the progression of AF [4, 5]. In 2016, the European Heart Rhythm Association postulated the concept of atrial cardiomyopathy, emphasizing the importance of atrial structural remodelling in AF pathogenesis. In the present study, a comparison of the clinical echocardiography materials of patients with AF or SR showed that the atrial diameter and the levels of proteins encoded by hypertrophy-related genes were much greater in the former, indicative of atrial hypertension in AF. These results were also consistent with the histopathologically characterized cardiomyocyte hypertrophy in EHRAS class I and III atrial cardiomyopathy [5].

4.2. Atrial Hypertrophy Promotes the Progression of Atrial Electrical and Functional Remodelling. The newly proposed atrial cardiomyopathy definitions highlight the tight relationship between structural, electrophysiological, and functional remodelling in atrial pathogenic substrates. Atrial
The atria significantly contribute to cardiac function [52, 53]. In addition to their impact on ventricular filling, they serve as a volume reservoir for pulmonary vein (PV), as a return to modulate left ventricular (LV) filling and cardiovascular performance during LV systole, as a conduit for PV return during early LV diastole, and as a booster pump that augments LV filling during late LV diastole [5]. Long-term maladaptive atrial hypertrophy results in enlarged atrial volume and impaired atrial mechanical function. Hypertension-induced atrial hypertrophy reduces the left atrial emptying fraction [49], with atrial hypertrophy-induced left atrial dilation also contributing to a loss of atrial mechanical function, which in turn leads to disability [54]. Thus, increased atrial volume may represent a marker of impaired atrial performance and daily activities in older individuals [54].

4.3. Nuclear Epigenetic Mechanisms Contribute to the Transcriptional Regulation of Atrial Hypertrophy. Emerging evidence suggests that epigenetic mechanisms are involved in cardiac remodelling [13]. We observed enhanced H3K27ac and H4ac enrichment in promoters of hypertrophy-related genes in atrial tissues from AF. The associated “loose” epigenetic environment would provide sufficient space for cardiac transcription factors to interact with promoter DNA sequences and favour the transcription of hypertrophy-related genes. We also investigated whether the acquisition of H3K27ac and H4ac might assist MEF2 binding to the promoters of the hypertrophy-related genes. Collectively, the data presented in Figure 5 suggest a model whereby the histone modification of H4ac and H3K27ac at the promoter may provide a loosen chromatin environment that is permissive for the recruitment of MEF2. Thus, H3K27ac and H4Ac facilitate a “relaxed” chromatin structure that provides accessible promoter DNA for recognition by MEF2, further facilitating its binding to promoters of hypertrophy-related genes.

Our results demonstrate that the hypertrophy stimulus AngII-induced exclusion of HDAC4 and HDAC5 from the hypertrophy-related gene promoter regions was accompanied by reversible increased enrichment of MEF2. We speculate that in physiological conditions, class II HDACs form a complex with MEF2 on gene regulatory elements harbouring MEF2-binding sites, resulting in gene repression. AngII-induced exclusion of HDAC4 and HDAC5 from the promoter regions released MEF2-binding sites, promoting MEF2-promoter-binding and facilitating the transcription of hypertrophy-related genes. The HAT P300 has also been shown to dock with the same domain of MEF2 that is occupied by class II HDACs [45]. Thus, MEF2 may act as a platform to respond to positive or negative transcriptional signals by exchanging HATs and class II HDACs.

Transcriptional repression by class II HDACs strongly depended on their subcellular shuttling. HDAC4, HDAC5, HDAC7, and HDAC9 were found to have three conserved serine sites at the N-terminal domain [55]. Phosphorylation of at least one of these sites permits the connection with the chaperone 14-3-3, exposing the C-terminal nuclear export signal [42] and inducing shuttling from the nucleus to the cytoplasm. The shuttling of HDAC4 and HDAC5 from the nucleus to cytoplasm mediated by AngII phosphorylation may contribute to the exclusion of HDAC4 and HDAC5 from the chromatin of hypertrophy-related gene promoter regions. HDAC-induced deacetylation of histones in nucleosomes induces chromatin condensation and gene transcription repression by preventing the binding of transcription factors such as MEF2 and other components of the...
transcriptional machinery to gene promoter and enhancer regions. Thus, the cytoplasm nucleus translocation of class II HDACs may constitute a novel epigenetic mechanism regulating the transcription of hypertrophy-related genes.

4.4. Cytoplasmic CaMKII/PKD Pathways Are Involved in the Transcriptional Regulation of Atrial Hypertrophy. Signalling pathways that target gene expression may be applied to regulate hypertrophy-related gene expression. PKD belongs to the CaMK superfamily, the members of which exhibit regulatory effects on class IIa HDACs[56]. HDAC5 was previously identified as a phosphorylation target of PKD[56]. Cardiac-specific deletion of PKD in turn leads to protection from prohypertrophic stimuli (e.g., pressure overload via transverse aortic constriction chronic β-adrenergic stimulation with isoprenaline, chronic AngII stimulation)[57]. Unlike PKD, CaMKII selectively phosphorylates HDAC4, suggesting a role for HDAC4 in CaMKII-dependent gene expression. Adrenergic receptor agonists, AngII and endothelin enhance CaMKII activity via G-protein receptor signalling[58]. In particular, AngII-induced hypertrophy-related gene expression and nuclear export of HDAC4 and HDAC5 could be ameliorated by PKD and CaMKII inhibitors, suggesting that PKD and CaMKII may constitute the cytoplasmic pathways that regulate the hypertrophic progression of atrial cardiomyopathy.

4.5. Atrial Energy Remodelling May Serve as an Upstream Influencer of Atrial Structural Remodelling. Evidence also exists that mitochondrial energy dysfunction may also constitute an atrial arrhythmogenic substrate[47, 48]. Our RNA-Seq data showed that the quantity of cardiac energy metabolism genes such as mitochondrial transmembrane protein, components of mitochondrial respiratory chain complex, and adenosine triphosphate synthesis-coupled protein changed more significantly than cardiac genes in the early stage of AngII incubation (Figure 7). These energy genes are specifically expressed highly in the heart. The results of our study thus demonstrate a possible mechanistic link between early atrial mitochondrial energy remodelling and atrial structural remodelling. Atrial mitochondrial energy genes changed much earlier and more markedly than structural remodelling genes under the initial stage of the pathological condition, suggesting that atrial energy remodelling may serve as the earliest initiator that triggers all other atrial remodelling processes including structural, electrical, and functional remodelling. Atrial energy remodelling may in turn represent a potential upstream therapeutic target for inhibiting and reversing atrial structural, electrical, and functional remodelling. Notably, the AngII-induced atrial structural and energy remodelling effects and correlated epigenetic transcriptional regulation and activation of the transcription factor MEF2, subsequently causing atrial hypertrophy.

5. Conclusion
Atrial cardiomyopathy plays a key role in the pathogenesis of atrial dysfunction, AF, and cardiogenic stroke. Our results suggest a novel arrhythmogenic mechanism whereby epigenetic control of chromatin structure may play an important role in the progression of atrial cardiomyopathy (Figure 8). AngII induces histone acetylation via the cytoplasmic-nuclear shuttling of HDACs, which might provide a promising therapeutic strategy for atrial cardiomyopathy. Moreover, our findings will also fundamentally advance the fields of atrial function and atrial arrhythmogenesis research.

Data Availability
Data available on request: the first author Liuying Zheng can be contacted for data request. Her contact email is zhengliuyi27@163.com.
Disclosure

An poster presentation based on part of the data of this manuscript has been presented on the 2018 ESC Congress.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This work was supported by the National Natural Science Foundation of China, Health Science and Technology Project, and Sci- pal Health Bureau and Tianjin Chest Hospital Science Foundation. The manuscript has been presented on the 2018 ESC Congress. An poster presentation based on part of the data of this work to work with high-throughput sequencing data.

References

[1] W. Harvey, "Exercitatio anatomica de motu cordis et sanguinis in animalibus," Frankfurt am Main, vol. 1628, article 17, 1928.
[2] F. Bisbal, A. Baranchuk, E. Braunwald, A. Bayés de Luna, and A. Bayés-Genis, "Atrial failure as a clinical entity," Journal of the American College of Cardiology, vol. 75, no. 2, pp. 222–232, 2020.
[3] L. Thomas and W. P. Abbayaratna, "Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance," JACC: Cardiovascular Imaging, vol. 10, no. 1, pp. 65–77, 2017.
[4] B. Burstein and S. Nattel, "Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation," Journal of the American College of Cardiology, vol. 51, no. 8, pp. 802–809, 2008.
[5] A. Goette, J. M. Kalman, L. Aguina et al., "EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication," Europace, vol. 18, no. 10, pp. 1455–1490, 2016.
[6] L. Zheng, X. Jia, C. Zhang et al., "Angiotensin II in atrial structural remodeling: the role of Ang II/JAK/STAT3 signaling pathway," American Journal of Translational Research, vol. 7, no. 6, pp. 1021–1031, 2015.
[7] L. Zheng, M. Zhang, J. Xue et al., "Effect of angiotensin II on STAT3 mediated atrial structural remodeling," European Review for Medical and Pharmacological Sciences, vol. 18, no. 16, pp. 2365–2377, 2014.
[8] D. Levy, R. J. Garrison, D. D. Savage, W. B. Kannel, and W. P. Castelli, "Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study," The New England Journal of Medicine, vol. 322, no. 22, pp. 1561–1566, 1990.
[9] E. van Rooij, L. B. Sutherland, X. Qi, J. A. Richardson, J. Hill, and E. N. Olson, "Control of stress-dependent cardiac growth and gene expression by a micro RNA," Science, vol. 316, no. 5824, pp. 575–579, 2007.
[10] C. M. Ferrario, "Cardiac remodelling and RAS inhibition," Therapeutic Advances in Cardiovascular Disease, vol. 10, no. 3, pp. 162–171, 2016.
[11] S. M. Kolodziejczyk, L. Wang, K. Balaszi, Y. DeRepentigny, R. Kothary, and L. A. Megeny, "MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium," Current Biology, vol. 9, no. 20, pp. 1203–1206, 1999.
[12] T. C. Herzig, S. M. Jobe, H. Aoki et al., "Angiotensin II type 1 receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 14, pp. 7543–7548, 1997.
[13] Y. Cao, L. Lu, M. Liu et al., "Impact of epigenetics in the management of cardiovascular disease: a review," European Review for Medical and Pharmacological Sciences, vol. 18, no. 20, pp. 3097–3104, 2014.
[14] T. Kouzarides, "Chromatin modifications and their function," Cell, vol. 128, no. 4, pp. 693–705, 2007.
[15] A. Portela and M. Esteller, "Epigenetic modifications and human disease," Nature Biotechnology, vol. 28, no. 10, pp. 1057–1068, 2010.
[16] M. C. Filomena and M. L. Bang, "In the heart of the MEF2 transcription network: novel downstream effectors as potential targets for the treatment of cardiovascular disease," Cardiovascular Research, vol. 114, no. 11, pp. 1425–1427, 2018.
[17] C. Lemercier, A. Verdel, B. Galloo, S. Curtet, M. Brocard, and A. Bayés-Genís, "Atrial failure as a clinical entity:,, Journal of Molecular Biology, vol. 24, no. 19, pp. 8374–8385, 2004.
[18] A. Han, J. He, Y. Wu, J. O. Liu, and L. Chen, "Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2," Journal of Molecular Biology, vol. 345, no. 1, pp. 91–102, 2005.
[19] R. B. Vega, B. C. Harrison, E. Meadows et al., "Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5," Molecular and Cellular Biology, vol. 24, no. 19, pp. 8374–8385, 2004.
[20] A. Han, F. Pan, J. C. Stroud, H. D. Youn, J. O. Liu, and L. Chen, "Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2," Nature, vol. 422, no. 6933, pp. 730–734, 2003.
[21] Z. Sun, J. Han, W. Zhao et al., "TRPV1 activation exacerbates hypoxia/reoxygenation-induced apoptosis in H9C2 cells via calcium overload and mitochondrial dysfunction," International Journal of Molecular Sciences, vol. 15, no. 10, pp. 18362–18380, 2014.
[22] D. Kim, G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, and S. L. Salzberg, "TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions," Genome Biology, vol. 14, no. 4, pp. 1–13, 2013.
[23] S. Anders, P. T. Pyl, and W. Huber, "HTSeq—a python framework to work with high-throughput sequencing data," Bioinformatics, vol. 31, no. 2, pp. 166–169, 2015.
[24] M. D. Robinson, D. J. McCarthy, and G. K. Smyth, "edgeR: a Bioconductor package for differential expression analysis of digital gene expression data," Bioinformatics, vol. 26, no. 1, pp. 139–140, 2010.
[25] C. M. Ferrario and W. B. Strawn, "Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease," The American Journal of Cardiology, vol. 98, no. 1, pp. 121–128, 2006.
[26] Y. Kim, D. Phan, E. van Rooij et al., "The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice," Computational and Mathematical Methods in Medicine
The Journal of Clinical Investigation, vol. 118, no. 1, pp. 124–132, 2008.

R. J. van Oort, E. van Rooij, M. Bourajjaj et al., "MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure," Circulation, vol. 114, no. 4, pp. 298–308, 2006.

J. Backs and E. N. Olson, "Control of cardiac growth by histone acetylation/deacetylation," Circulation Research, vol. 98, no. 1, pp. 15–24, 2006.

S. Y. Roth, J. M. Denu, and C. D. Allis, "Histone acetyltransferases," Annual Review of Biochemistry, vol. 70, no. 1, pp. 81–120, 2001.

N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill, "Hypertrophy of the heart: a new therapeutic target?," Circulation, vol. 109, no. 13, pp. 1580–1589, 2004.

N. Frey and E. N. Olson, "Cardiac hypertrophy: the good, the bad, and the ugly," Annual Review of Physiology, vol. 65, no. 1, pp. 45–79, 2003.

J. Sadoshima and S. Izumo, "The cellular and molecular response of cardiac myocytes to mechanical stress," Annual Review of Physiology, vol. 59, no. 1, pp. 551–571, 1997.

L. Barki-Harrington, C. Perrino, and H. A. Rockman, "Network integration of the adrenergic system in cardiac hypertrophy," Cardiovascular Research, vol. 63, no. 3, pp. 391–402, 2004.

E. Bush, J. Fieltz, L. Melvin et al., "A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2870–2875, 2004.

T. A. McKinsey and E. N. Olson, "Cardiac histone acetylation--therapeutic opportunities abound," Trends in Genetics, vol. 20, pp. 206–213, 2004.

C. L. Zhang, T. A. McKinsey, S. Chang, C. L. Antos, J. A. Hill, and E. N. Olson, "Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy," Cell, vol. 110, no. 4, pp. 479–488, 2002.

J. Lu, T. A. McKinsey, R. L. Nicol, and E. N. Olson, "Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 8, pp. 4070–4075, 2000.

T. A. McKinsey, C. L. Zhang, and E. N. Olson, "Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 26, pp. 14400–14405, 2000.

R. Passier, H. Zeng, N. Frey et al., "CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo," The Journal of Clinical Investigation, vol. 105, no. 10, pp. 1395–1406, 2000.

T. A. McKinsey, C. L. Zhang, and E. N. Olson, "MEF2: a calcium-dependent regulator of cell division, differentiation and death," Trends in Biochemical Sciences, vol. 27, no. 1, pp. 40–47, 2002.

Y. S. Dai and B. E. Markham, "p300 functions as a coactivator of transcription factor GATA-4," The Journal of Biological Chemistry, vol. 276, no. 40, pp. 37178–37185, 2001.

T. A. McKinsey, C. L. Zhang, J. Lu, and E. N. Olson, "Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation," Nature, vol. 408, no. 6808, pp. 106–111, 2000.

J. Lu, T. A. McKinsey, C. L. Zhang, and E. N. Olson, "Regulation of skeletal myogenensis by association of the MEF2 transcription factor with class II histone deacetylases," Molecular Cell, vol. 6, no. 2, pp. 233–244, 2000.

C. L. Zhang, T. A. McKinsey, J. R. Lu, and E. N. Olson, "Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor," The Journal of Biological Chemistry, vol. 276, no. 1, pp. 35–39, 2001.

T. A. McKinsey, C. L. Zhang, and E. N. Olson, "Control of muscle development by dueling HATs and HDACs," Current Opinion in Genetics & Development, vol. 11, no. 5, pp. 497–504, 2001.

M. Parra, H. Kasler, T. A. McKinsey, E. N. Olson, and E. Verdin, "Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation," The Journal of Biological Chemistry, vol. 280, no. 14, pp. 13762–13770, 2005.

D. Montaigne, X. Marechal, P. Lefebvre et al., "Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome in whom post- operative atrial fibrillation develops," Journal of the American College of Cardiology, vol. 62, no. 16, pp. 1466–1473, 2013.

X. Zhang, Z. Zhang, Y. Zhao et al., "Aloginptin, a dipetidyl peptidase inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits," Journal of the American Heart Association, vol. 6, no. 5, article e005945, 2017.

P. M. Kistler, P. Sanders, M. Dodic et al., "Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation," European Heart Journal, vol. 27, no. 24, pp. 3045–3056, 2006.

D. H. Lau, L. Mackenzie, D. J. Kelly et al., "Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model," Heart Rhythm, vol. 7, no. 9, pp. 1282–1290, 2010.

A. Parikh, D. Patel, C. F. McTiernan et al., "Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts," Circulation Research, vol. 113, no. 3, pp. 313–321, 2013.

B. D. Hoit, "Left atrial size and function: role in prognosis," Journal of the American College of Cardiology, vol. 63, no. 6, pp. 493–505, 2014.

U. Schotten, S. Verheule, P. Kirchhof, and A. Goette, "Pathophysiological mechanisms of atrial fibrillation: a translational appraisal," Physiological Reviews, vol. 91, no. 1, pp. 265–325, 2011.

A. A. Pellett, L. Myers, M. Welsch, S. M. Jazwinski, and D. A. Welsh, "Left atrial enlargement and reduced physical function during aging," Journal of Aging and Physical Activity, vol. 21, no. 4, pp. 417–432, 2013.

C. M. Grozinger and S. L. Schreiber, "Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization," Proceedings of the National Academy of Sciences, vol. 97, no. 14, pp. 7835–7840, 2000.
[56] T. A. McKinsey, “Derepression of pathological cardiac genes by members of the CaM kinase superfamily,” Cardiovascular Research, vol. 73, no. 4, pp. 667–677, 2007.

[57] J. Fielitz, M. S. Kim, J. M. Shelton et al., “Requirement of protein kinase D1 for pathological cardiac remodeling,” Proceedings of the National Academy of Sciences, vol. 105, no. 8, pp. 3059–3063, 2008.

[58] M. E. Anderson, J. H. Brown, and D. M. Bers, “CaMKII in myocardial hypertrophy and heart failure,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 4, pp. 468–473, 2011.